Adele brings decades of finance and healthcare experience to 1315 Capital, including 20 years in private equity. Throughout her investing career, she has focused on commercial-stage specialty pharmaceutical, medical technology, and healthcare service investments.
Adele co-founded 1315 Capital in 2015 to establish a firm focused on healthcare growth investing. Adele was recruited to Quaker Partners in 2007 to expand its growth- and expansion-stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, a global private equity firm, where she started in 1997.
Forbes has recognized Adele on its "Midas List" of top 100 technology investors worldwide, top 10 life science investors, and top women in venture capital.
Adele has served on the boards of many high-growth companies including Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.
Prior to entering private equity as a Kauffman Fellow, Adele built a strong foundation in finance and healthcare at CoreStates in commercial banking and at Baxter Healthcare in marketing and business development.
Education, Personal, and Fellowship
Adele is a graduate of Saint Joseph's University and has an MBA from Cornell University, where she was awarded a Fried Fellowship. Adele is a Founder and President of the Private Equity Women’s Investor Network, and is on the Board of Visitors of the Haub School of Business at St. Joseph’s University.
Adele is a member of Kauffman Fellows Class 3 and served her fellowship under mentor Janet Effland at Apax Partners (formerly Patricof & Co.) in Menlo Park, CA. She was also a mentor for Class 14 member Sanjay Mistry.